Dr. Volker Gerdts, VIDO Director

USask’s VIDO begins COVID-19 vaccine clinical trials at CCfV

Posted on

The first volunteers have been selected for a vaccine trial of COVAC-2, a COVID-19 vaccine developed by the Vaccine and infectious Disease Organization (VIDO) at the University of Saskatchewan (USask).

“We are excited to start clinical trials,” said VIDO Director Dr. Volker Gerdts. “Our team has worked hard to advance the development of this vaccine to help combat the COVID-19 pandemic.” 

The trial was designed as a combined Phase 1/Phase 2 study. Phase 1 will vaccinate 108 healthy volunteers in a placebo-controlled study at the Canadian Center for Vaccinology (CCfV) in Halifax. Two doses will be administered to each volunteer 28 days apart….


Read More Impact Stories

Posted on
This article is only available in French. Lésion de la moelle épinière: stimuler la plasticité des neurones pour améliorer la [...]
Posted on
A comprehensive study by scientists at UdeM maps the evolutionary dynamics and risks of viral emergence of diseases that could [...]
Posted on
This article is available only in French. Infections respiratoires: mieux trier les patients pour soulager la pression sur les urgences [...]